Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vifor Pharma Ag (GNHAF)

Vifor Pharma Ag (GNHAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.01
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.9906 unch
on 10/23/19
159.6505 -3.55%
on 10/01/19
+2.7589 (+1.82%)
since 07/25/19
3-Month
149.7500 +2.83%
on 07/24/19
159.6505 -3.55%
on 10/01/19
+10.4906 (+7.31%)
since 07/10/19
52-Week
123.9861 +24.20%
on 03/07/19
159.6505 -3.55%
on 10/01/19
+2.8906 (+1.91%)
since 10/08/18

Most Recent Stories

More News
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer

Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage,...

AQXP : 3.68 (+6.05%)
ABUS : 2.33 (-2.51%)
GNHAF : 153.9906 (-3.55%)
NGEN.VN : 1.430 (-0.69%)
NGENF : 1.0900 (unch)
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously

Regulatory News:

GNHAF : 153.9906 (-3.55%)
Janssen's INVOKANA (canagliflozin) Gets Boost Over Competitors with FDA Approval for Diabetic Kidney Disease and a Newly Minted Collaboration with Renal Giant, Vifor Pharma

It is well-documented that nearly half of patients with type 2 diabetes will eventually develop diabetic kidney disease (DKD), which is the most common cause of kidney failure in the United States. INVOKANA,...

GNHAF : 153.9906 (-3.55%)
Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee

Regulatory News:

GNHAF : 153.9906 (-3.55%)
Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

CELGZ : 0.47 (+2.15%)
NVS : 92.99 (-0.08%)
NVO : 57.25 (+1.33%)
GNHAF : 153.9906 (-3.55%)
Evotec And Vifor Pharma Form Joint Venture For Early Development In Nephrology

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Vifor Pharma today announced the launch of a 50:50 joint venture focused on the discovery and development of novel nephrology...

CELGZ : 0.47 (+2.15%)
NVS : 92.99 (-0.08%)
NVO : 57.25 (+1.33%)
GNHAF : 153.9906 (-3.55%)
Vifor Pharma and Evotec form joint venture for early development in nephrology

Regulatory News:

GNHAF : 153.9906 (-3.55%)
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen

Regulatory News:

JNJ : 141.38 (+0.03%)
GNHAF : 153.9906 (-3.55%)
Vifor Pharma Appoints New Chief Medical Officer and Announces Changes to Executive Committee

Regulatory News:

GNHAF : 153.9906 (-3.55%)
Vifor Pharma announces the initiation of S&P credit rating coverage with an investment grade rating

Regulatory News:

GNHAF : 153.9906 (-3.55%)
Trade GNHAF with:

Key Turning Points

2nd Resistance Point 153.9906
1st Resistance Point 153.9906
Last Price 153.9906
1st Support Level 153.9906
2nd Support Level 153.9906

See More

52-Week High 159.6505
Last Price 153.9906
Fibonacci 61.8% 146.0267
Fibonacci 50% 141.8183
Fibonacci 38.2% 137.6099
52-Week Low 123.9861

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar